Alex Zhavoronkov: Linking Chemistry and Biology Using Artificial Intelligence
The team at Insilico Medicine has recently reported that they achieved a major milestone for their comprehensive artificial intelligence (AI)-based drug discovery system: a novel molecule for a novel target discovered with their AI demonstrated efficacy in a broad therapeutic area and reached preclinical candidate stage in Idiopathic Pulmonary Fibrosis (IPF).
Insilico Medicine is a Hong Kong-based company that pioneered the application of deep learning, specifically -- generative adversarial networks (GANs), for drug discovery and generative chemistry.
Dr. Alex Zhavoronkov, Co-founder and CEO of Insilico Medicine, agreed to answer several questions about his path into biotech, the company, the discovery, and how they managed to build an end-to-end AI system capable of uncovering novel targets and molecules, linking biology and chemistry into an integral research process.
Topics: AI & Digital
